Disability Benefits for Myelodysplastic Syndrome

How SSA Evaluates Myelodysplastic Syndrome

Myelodysplastic syndrome (MDS) is a group of disorders in which the bone marrow produces poorly formed, ineffective blood cells, leading to low counts of red cells, white cells, or platelets — and, in some people, progressing toward acute leukemia. The Social Security Administration evaluates MDS under Blue Book listing 7.10, disorders of bone marrow failure, and under listing 7.17 following a bone marrow or stem cell transplant.

Listing 7.10 is met when the disorder requires life-sustaining treatment, most commonly shown by:

• Frequent transfusions. A documented need for red blood cell or platelet transfusions on average at least once every six weeks.
• Serious, recurrent complications of the marrow failure or its treatment, such as severe infections or bleeding requiring hospitalization.

If MDS is treated with a stem cell transplant, listing 7.17 applies and SSA considers you disabled for at least 12 months from the transplant date, with later reassessment based on recovery and complications such as graft-versus-host disease. If the disease progresses to acute leukemia, it is evaluated under the cancer listings (13.06), which are more readily met. Because MDS most often affects older adults and tends to worsen over time, SSA considers the full effect of low counts across all cell lines. The impairment must last at least 12 months.

Medical Evidence SSA Needs for Myelodysplastic Syndrome

The diagnosis of MDS depends on blood and bone marrow testing, so those records are essential: complete blood counts documenting low or dysfunctional cell lines over time, and the bone marrow biopsy and aspiration report describing the abnormal cells and, ideally, the risk category (for example, an IPSS score). Cytogenetic and molecular testing helps establish severity and prognosis.

Because listing 7.10 turns on treatment intensity, transfusion records are pivotal: the dates and frequency of red cell and platelet transfusions show whether you meet the six-week threshold. Document the broader treatment course too — growth factors, hypomethylating agents, other medications, and any transplant — and your response.

Records of complications carry weight: serious infections from low white counts, bleeding from low platelets, hospitalizations, and any progression toward leukemia. Hematology notes summarizing the disease complete the file.

Qualifying Through Your Residual Functional Capacity

MDS that does not quite meet the transfusion frequency of listing 7.10 is still frequently disabling, and the residual functional capacity stage addresses it. The anemia of MDS causes profound fatigue and breathlessness on exertion, limiting lifting, standing, walking, and the ability to sustain any physical activity — restrictions that generally point to sedentary work, with a need for rest breaks.

Low white cell counts increase infection risk, supporting avoidance of crowded or high-exposure workplaces and often causing unpredictable illness-related absences. Low platelets add bleeding risk that rules out hazardous work. On top of these, the time spent on transfusions, chemotherapy-type treatments, and close monitoring produces frequent absences that competitive employment does not accommodate.

Because MDS is most common in older adults, the medical-vocational grid rules are often decisive: a claimant 50 or older limited to sedentary work, with a physical work history and no transferable skills, is generally found disabled. Younger claimants prevail by documenting fatigue, infection risk, and absences that preclude even sedentary work.

Tips for a Stronger Myelodysplastic Syndrome Claim

Document treatment intensity and the toll of low counts.

• Track every transfusion with dates; the six-week average in listing 7.10 rests on those records.
• Keep all blood counts and your bone marrow reports, including any risk score, so SSA sees the severity.
• Report infections and bleeding episodes, and keep records of any hospitalizations.
• If a stem cell transplant is planned or completed, submit those records — they can secure at least a year of benefits under listing 7.17.
• Ask your blood doctor to describe how fatigue, infection risk, and treatment schedules limit your ability to work reliably.